
Augustine Kunle Obisesan
Examiner (ID: 8490, Phone: (571)272-2020 , Office: P/2156 )
| Most Active Art Unit | 2156 |
| Art Unit(s) | 2169, 2156 |
| Total Applications | 825 |
| Issued Applications | 506 |
| Pending Applications | 72 |
| Abandoned Applications | 275 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16108403
[patent_doc_number] => 20200206224
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
[patent_app_type] => utility
[patent_app_number] => 16/809850
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16809850
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/809850 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | Mar 4, 2020 | Issued |
Array
(
[id] => 16090319
[patent_doc_number] => 20200199146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => Transplantation Therapies
[patent_app_type] => utility
[patent_app_number] => 16/810769
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7578
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810769
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810769 | Transplantation Therapies | Mar 4, 2020 | Abandoned |
Array
(
[id] => 16090317
[patent_doc_number] => 20200199145
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => Transplantation Therapies
[patent_app_type] => utility
[patent_app_number] => 16/810738
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810738
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810738 | Transplantation Therapies | Mar 4, 2020 | Abandoned |
Array
(
[id] => 16236728
[patent_doc_number] => 20200253962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => TREATMENT OF VASOMOTOR SYMPTOMS
[patent_app_type] => utility
[patent_app_number] => 16/810273
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810273
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810273 | TREATMENT OF VASOMOTOR SYMPTOMS | Mar 4, 2020 | Abandoned |
Array
(
[id] => 17633810
[patent_doc_number] => 11344514
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-31
[patent_title] => Dosage forms and methods for enantiomerically enriched or pure bupropion
[patent_app_type] => utility
[patent_app_number] => 16/807512
[patent_app_country] => US
[patent_app_date] => 2020-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12185
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/807512 | Dosage forms and methods for enantiomerically enriched or pure bupropion | Mar 2, 2020 | Issued |
Array
(
[id] => 17633809
[patent_doc_number] => 11344513
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-31
[patent_title] => Dosage forms and methods for enantiomerically enriched or pure bupropion
[patent_app_type] => utility
[patent_app_number] => 16/806145
[patent_app_country] => US
[patent_app_date] => 2020-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12174
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806145
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/806145 | Dosage forms and methods for enantiomerically enriched or pure bupropion | Mar 1, 2020 | Issued |
Array
(
[id] => 16072089
[patent_doc_number] => 20200190031
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => ARYL ETHERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/795697
[patent_app_country] => US
[patent_app_date] => 2020-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 98966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795697
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/795697 | ARYL ETHERS AND USES THEREOF | Feb 19, 2020 | Abandoned |
Array
(
[id] => 16009049
[patent_doc_number] => 20200179367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => Method of Treating Coronavirus
[patent_app_type] => utility
[patent_app_number] => 16/792492
[patent_app_country] => US
[patent_app_date] => 2020-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792492
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/792492 | Method of treating coronavirus | Feb 16, 2020 | Issued |
Array
(
[id] => 16335556
[patent_doc_number] => 10786493
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-29
[patent_title] => Method of treating viral infections
[patent_app_type] => utility
[patent_app_number] => 16/791290
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 23214
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791290
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/791290 | Method of treating viral infections | Feb 13, 2020 | Issued |
Array
(
[id] => 18995861
[patent_doc_number] => 11912688
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => 1, 3-dioxolane derivative
[patent_app_type] => utility
[patent_app_number] => 17/430884
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 29
[patent_no_of_words] => 7010
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430884
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/430884 | 1, 3-dioxolane derivative | Feb 13, 2020 | Issued |
Array
(
[id] => 16009107
[patent_doc_number] => 20200179396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 16/790085
[patent_app_country] => US
[patent_app_date] => 2020-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21420
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16790085
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/790085 | Pharmaceutical compositions comprising meloxicam | Feb 12, 2020 | Issued |
Array
(
[id] => 16009045
[patent_doc_number] => 20200179365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => Method of Regulating Tumor Necrosis Factor-alpha (TNF-alpha) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation
[patent_app_type] => utility
[patent_app_number] => 16/785747
[patent_app_country] => US
[patent_app_date] => 2020-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16785747
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/785747 | Method of regulating tumor necrosis factor-alpha (TNF-a) for treating cancers, autoimmune disorders, and other disorders associated with chronic inflammation | Feb 9, 2020 | Issued |
Array
(
[id] => 18201142
[patent_doc_number] => 11583513
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-21
[patent_title] => Semifluorinated alkane compositions
[patent_app_type] => utility
[patent_app_number] => 16/783972
[patent_app_country] => US
[patent_app_date] => 2020-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7342
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783972
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/783972 | Semifluorinated alkane compositions | Feb 5, 2020 | Issued |
Array
(
[id] => 18871173
[patent_doc_number] => 11858959
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-02
[patent_title] => Glycyrrhetinic acid derivatives for use in treating hyperkalemia
[patent_app_type] => utility
[patent_app_number] => 17/429599
[patent_app_country] => US
[patent_app_date] => 2020-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 50795
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 361
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429599
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/429599 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | Feb 5, 2020 | Issued |
Array
(
[id] => 17726613
[patent_doc_number] => 11382978
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => Percutaneous absorption composition
[patent_app_type] => utility
[patent_app_number] => 16/782988
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4582
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782988
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782988 | Percutaneous absorption composition | Feb 4, 2020 | Issued |
Array
(
[id] => 15960385
[patent_doc_number] => 20200163944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF LIFE
[patent_app_type] => utility
[patent_app_number] => 16/778845
[patent_app_country] => US
[patent_app_date] => 2020-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10603
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778845
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/778845 | Topical roflumilast formulation having improved delivery and plasma half life | Jan 30, 2020 | Issued |
Array
(
[id] => 17241911
[patent_doc_number] => 20210361654
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => METHODS OF TREATING A VASCULAR LEAKAGE-ASSOCIATED DISEASE OR DISORDER
[patent_app_type] => utility
[patent_app_number] => 16/755008
[patent_app_country] => US
[patent_app_date] => 2020-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10697
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755008
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/755008 | Methods of treating a vascular leakage-associated disease or disorder | Jan 28, 2020 | Issued |
Array
(
[id] => 16138963
[patent_doc_number] => 10702535
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-07
[patent_title] => Pharmaceutical compositions comprising meloxicam
[patent_app_type] => utility
[patent_app_number] => 16/773567
[patent_app_country] => US
[patent_app_date] => 2020-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 13
[patent_no_of_words] => 14814
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773567
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/773567 | Pharmaceutical compositions comprising meloxicam | Jan 26, 2020 | Issued |
Array
(
[id] => 16175460
[patent_doc_number] => 20200222428
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => Compositions and Methods for Treating Eyes and Methods of Preparation
[patent_app_type] => utility
[patent_app_number] => 16/751177
[patent_app_country] => US
[patent_app_date] => 2020-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751177
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/751177 | Compositions and methods for treating eyes and methods of preparation | Jan 22, 2020 | Issued |
Array
(
[id] => 16253449
[patent_doc_number] => 20200262823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => METHODS OF TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/749073
[patent_app_country] => US
[patent_app_date] => 2020-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44286
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16749073
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/749073 | METHODS OF TREATING CANCER | Jan 21, 2020 | Abandoned |